Heparin-induced extracorporeal LDL precipitation (HELP) eliminates selectively fibrinogen, LDL cholesterol, cholesterol, triglycerides and LP(a) from the blood plasma using extracorporeal circulation. The reduction of fibrinogen and LDL about 50% after only one procedure immediately improves the hemorrheological situation, which has so far not been achieved by any hemorrheologically active substance. Five patients (1 central retinal vein occlusion, 3 branch vein occlusions, 1 central arterial occlusion) ranging from 59-76 years underwent HELP treatment six times over a 5-week period. After the first HELP procedure the fibrinogen was lowered from 278 +/- 57.8 to 157 +/- 22.2 mg/dl and LDL from 162.2 +/- 58 to 82.4 +/- 32.5 mg/dl. Plasma viscosity decreased from 1.3 +/- 0.07 to 1.1 +/- 0.05 mPa/s. At the end of the treatment an increase in visual acuity of 3 or more lines and an improvement in the visual field was seen in all patients. Measurements of the arteriovenous passage time with laser scan video fluorescein angiography before and at the end of the therapy showed a significant decrease from 3.5 +/- 1.59 to 2.88 +/- 1.54 s (P < 0.05) without influencing the arm-retina time. This first clinical and hemorrheological data on the HELP procedure in retinal vessel occlusion demonstrate a promising regimen in the treatment of acute retinal microcirculatory diseases.

Download full-text PDF

Source

Publication Analysis

Top Keywords

extracorporeal ldl
8
ldl precipitation
8
precipitation help
8
fibrinogen ldl
8
help procedure
8
+/-
8
ldl
5
help
5
[heparin-induced extracorporeal
4
help therapeutic
4

Similar Publications

Arterial hypertension and increased atherogenic index of plasma (AIP) are strong predictors of cardiovascular risk associated in individuals with obesity both in adults and children. Thus, we aimed to explore the relationship between AIP and systolic ambulatory blood pressure index (sABPI) with left ventricular geometry pattern in obese children. In this cross-sectional study, a total of 129 obese children (BMI greater or equal to the 95th percentile for age and sex) were examined.

View Article and Find Full Text PDF

Management of a young HoFH patient during pregnancy using Lipoprotein Apheresis (whole blood): A novel experience.

Transfus Apher Sci

December 2024

Department of Maternal and Child Health and Urological Sciences, Umberto I Hospital, "Sapienza" University of Rome, Viale del Policlinico 155, Rome 00161, Italy. Electronic address:

The pregnancy of a patient with homozygous familial hypercholesterolemia (HoFH) represents a challenge in the clinical setting due to the high cardiovascular risk of the mother and maternal-fetal morbidity. The lipid lowering drugs are generally contraindicated and lipoprotein apheresis (LA) is the only accepted treatment in HoFH pregnant woman. Liposorber D, an LA technique on whole blood, has good efficacy, safety, and short operative time.

View Article and Find Full Text PDF

Causal effects of lipid-lowering drugs on skin diseases: a two-sample Mendelian randomization study.

Front Med (Lausanne)

September 2024

Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Dermatology and STD, The Third Central Hospital of Tianjin, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.

Article Synopsis
  • The study explores the causal relationship between lipid-lowering drugs and skin conditions, focusing on LDL's potential role in skin cancers and psoriasis.
  • Using advanced statistical methods like Mendelian randomization, researchers analyzed genetic data to assess the effects of two specific drugs: HMGCR inhibitors (like statins) and PCSK9 inhibitors (like alirocumab).
  • Results indicate that HMGCR inhibitors are linked to a lower risk of nonmelanoma skin cancer and psoriasis, while PCSK9 inhibitors also show promise in reducing psoriasis risk among Europeans.
View Article and Find Full Text PDF

Retinopathy, small fiber neuropathy (SFN), and encephalopathy associated with recoverin antibodies have not been previously reported as side effects of BNT162b2 vaccination in a patient with HLA-B27-associated spondylarthritis. The patient is a 47-year-old male with a 10-year history of HLA-B27-associated spondylarthritis without recurrence, who developed acute and post-acute COVID vaccination syndrome (ACVS/PACVS) after the first dose of the BNT162b2 vaccine. The PACVS manifested as cerebral disease, eye disease, and SFN.

View Article and Find Full Text PDF

Background And Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by severely elevated LDL cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. In the pivotal Phase 3 HoFH trial (NCT03399786), evinacumab significantly decreased LDL-C in patients with HoFH. This study assesses the long-term safety and efficacy of evinacumab in adult and adolescent patients with HoFH.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!